Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Target Lesion Clear all
Recruiting Not applicable Interventional

Target Muscle Re-innervation and Regenerative Peripheral Nerve Interfaces Alone and in Combination for the Treatment of Residual and Phantom Limb Pain in Cancer Patients Who Have Received an Amputation

NCT06840262
View directory record Official record
Conditions
Amputation
Interventions
Questionnaire Administration, Regenerative Peripheral Nerve Interface Surgery, Targeted Muscle Reinnervation
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 1:13 AM EDT
Completed No phase listed Observational

Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial

NCT07255482
View directory record Official record
Conditions
Thyroid Nodule (Benign), Thyroid Nodule (Diagnosis), Thyroid Cancer
Interventions
Thyroid Ultrasound
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 25, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes

NCT00064727
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Avandia (Rosiglitazone), Avanclia (Rosiqlitazone)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 1:13 AM EDT
Enrolling by invitation Phase 2 Interventional

rTMS Target Identification for Functional Disability in AUD+mTBI

NCT04043442
View directory record Official record
Conditions
Alcohol Use Disorder, Mild Traumatic Brain Injury
Interventions
Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
22 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 25, 2026, 1:13 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Endothelial Dysfunction After SCI

NCT07227727
View directory record Official record
Conditions
Spinal Cord Injuries, Endothelial Dysfunction
Interventions
Intra-arterial Infusion of Vasoactive Agents, Intra-arterial Vitamin C Infusion, Blood Sampling
Procedure
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 25, 2026, 1:13 AM EDT
Recruiting Phase 1 Interventional

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

NCT06193486
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
MSGV1-PSCA-8T28Z, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 25, 2026, 1:13 AM EDT
Completed Phase 1 Interventional Results available

INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas

NCT04295759
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, DIPG, High-grade Astrocytoma NOS, CNS Primary Tumor, NOS (Malignant Glioma)
Interventions
INCB7839
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 1:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism of Bioactive Dietary Polyphenol Preparation (BDPP)

NCT04421079
View directory record Official record
Conditions
Healthy Control
Interventions
Trans-resveratrol, Concord grape juice, Grape seed polyphenol extract, Placebo
Dietary Supplement · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 25, 2026, 1:13 AM EDT
Completed No phase listed Observational

Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions

NCT02418494
View directory record Official record
Conditions
High Grade Anal Canal Squamous Intraepithelial Neoplasia, HIV Infection
Interventions
Concept Elicitation, Comprehension Assessment
Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
35 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Oct 25, 2026, 1:13 AM EDT
Recruiting Phase 2 Interventional

Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial

NCT06854224
View directory record Official record
Conditions
Suicide Risk, Major Depressive Disorder (MDD)
Interventions
Suvorexant (dual orexin receptor antagonist)
Drug
Lead sponsor
Marianne Goodman
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 25, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

The Randomized OPTIMAL-ACT Trial

NCT03772613
View directory record Official record
Conditions
Coronary Artery Disease, Ischemic Heart Disease, Anticoagulant-induced Bleeding, Coronary Syndrome
Interventions
Unfractionated heparin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 25, 2026, 1:13 AM EDT
Completed Not applicable Interventional Results available

Time in Glucose Hospital Target

NCT05135676
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Blinded CGM, real-time CGM
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 1:13 AM EDT
Completed No phase listed Observational

DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma

NCT01190943
View directory record Official record
Conditions
Localized Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 25, 2026, 1:13 AM EDT
Recruiting Not applicable Interventional

Intervening on Opioid Use and Loneliness

NCT06458335
View directory record Official record
Conditions
Opioid Use Disorder, Loneliness, Social Isolation
Interventions
Cognitive-Behavioral Therapy for Perceived Social Isolation, Health Education
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 25, 2026, 1:13 AM EDT
Not yet recruiting No phase listed Observational

SnapChole: An International, Time-Bound Prospective Platform Study of Management Strategies and Outcomes in Acute Calculous Cholecystitis

NCT07568080
View directory record Official record
Conditions
Cholecystitis, Acute
Interventions
Not listed
Lead sponsor
European Society for Trauma and Emergency Surgery
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 1:13 AM EDT
Completed Phase 3 Interventional Results available

Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)

NCT04385303
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Lorecivivint, Placebo
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 25, 2026, 1:13 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens

NCT02625155
View directory record Official record
Conditions
Target Drug-related Adverse Events
Interventions
Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
Other
Lead sponsor
InSource Diagnostics
Industry
Eligibility
12 Years and older
Enrollment
14,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Tazewell, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 25, 2026, 1:13 AM EDT
Completed Phase 2 Interventional

GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

NCT01854294
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GM604, Placebo comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 25, 2026, 1:13 AM EDT
Completed Phase 1 Interventional

Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

NCT01335256
View directory record Official record
Conditions
Neoplasms
Interventions
BAY1000394
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • St Louis, Missouri • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 25, 2026, 1:13 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

NCT01191268
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, LY2189265, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
36
States / cities
Concord, California • La Mesa, California • Lancaster, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 25, 2026, 1:13 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Premotor Cortex: A New Target for Stroke Motor Rehabilitation

NCT02565199
View directory record Official record
Conditions
Stroke
Interventions
rTMS over Premotor Cortex (Contralateral Hemisphere), rTMS over Premotor Cortex (Ipsilateral Hemisphere), rTMS (Control 1), rTMS (Control 2), rTMS (Control 3), Motor Training
Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 25, 2026, 1:13 AM EDT
Completed Not applicable Interventional Results available

FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer

NCT01243619
View directory record Official record
Conditions
Esophageal Cancer
Interventions
3'-deoxy-3'-(18) F-fluorothymidine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 25, 2026, 1:13 AM EDT
Recruiting Phase 2 Interventional

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

NCT06976853
View directory record Official record
Conditions
Crohn Disease (CD)
Interventions
Tirzepatide, Standard of care treatment
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Beverly Hills, California • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 25, 2026, 1:13 AM EDT
Active, not recruiting Phase 1 Interventional

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

NCT02498912
View directory record Official record
Conditions
Solid Tumors
Interventions
Production of Genetically-modified T cells, Cyclophosphamide, IP Catheter Insertion, Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells, Fludarabine
Procedure · Drug · Device + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 1:13 AM EDT